Biotech Values

[biomaven0]

Well NICE is not the standard we should be looking at - they basically will make up excuses not to pay. They won't pay for 2nd -line TKI's in CML, for example, claiming their benefits have not been well established, which is ridiculous. They are going to apply their made-up standards to expensive drugs in any class - not just oncology.

Peter